These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

137 related items for PubMed ID: 1317477

  • 21. Effect of enalapril on blood pressure, renal function, and the renin-angiotensin-aldosterone system in cats with autosomal dominant polycystic kidney disease.
    Miller RH, Lehmkuhl LB, Smeak DD, DiBartola SP, Radin J.
    Am J Vet Res; 1999 Dec; 60(12):1516-25. PubMed ID: 10622161
    [Abstract] [Full Text] [Related]

  • 22. Improved renal function during chronic lisinopril treatment in moderate to severe primary hypertension.
    Dupont AG, Van der Niepen P, Volckaert A, Ingels M, Bossuyt AM, Jonckheer MH, Six RO.
    J Cardiovasc Pharmacol; 1987 Dec; 10 Suppl 7():S148-50. PubMed ID: 2485052
    [Abstract] [Full Text] [Related]

  • 23. Effect of statin and angiotensin-converting enzyme inhibition on structural and hemodynamic alterations in autosomal dominant polycystic kidney disease model.
    Zafar I, Tao Y, Falk S, McFann K, Schrier RW, Edelstein CL.
    Am J Physiol Renal Physiol; 2007 Sep; 293(3):F854-9. PubMed ID: 17581927
    [Abstract] [Full Text] [Related]

  • 24. Cost-effectiveness of angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers as first-line treatment in autosomal dominant polycystic kidney disease.
    Clark LA, Whitmire S, Patton S, Clark C, Blanchette CM, Howden R.
    J Med Econ; 2017 Jul; 20(7):715-722. PubMed ID: 28332417
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Renal actions of the new angiotensin converting enzyme inhibitor CGS 16617.
    Levens NR.
    Arch Int Pharmacodyn Ther; 1988 Jul; 292():266-80. PubMed ID: 2840040
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Renal hemodynamics and renal kinins after angiotensin-converting enzyme inhibition.
    Clappison BH, Anderson WP, Johnston CI.
    Kidney Int; 1981 Nov; 20(5):615-20. PubMed ID: 6283229
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Prostacyclin in endotoxemia-induced acute kidney injury: cyclooxygenase inhibition and renal prostacyclin synthase transgenic mice.
    Wang W, Zolty E, Falk S, Summer S, Stearman R, Geraci M, Schrier R.
    Am J Physiol Renal Physiol; 2007 Oct; 293(4):F1131-6. PubMed ID: 17652370
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Are the renal haemodynamic and natriuretic effects of calcium antagonists and angiotensin converting inhibitors additive?
    Natov S, Hannedouche T, Schmitt F, Ikeni A, Déchaux M, Kirkisseli S, Lacour B, Grünfeld JP.
    J Hypertens Suppl; 1991 Dec; 9(6):S392-3. PubMed ID: 1819003
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. The angiotensin converting enzyme inhibitor enalapril and its effects on renal function.
    de Zeeuw D, Navis GJ, Donker AJ, de Jong PE.
    J Hypertens Suppl; 1983 Oct; 1(1):93-7. PubMed ID: 6100614
    [Abstract] [Full Text] [Related]

  • 40. Renal and endocrine effects of long-term converting enzyme inhibition as compared with calcium antagonism in essential hypertension.
    Katzman PL, Henningsen NC, Fagher B, Thulin T, Hulthén UL.
    J Cardiovasc Pharmacol; 1990 Mar; 15(3):360-4. PubMed ID: 1691357
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.